Medical Devices Regulation (EU) 2017/745

Medical Devices Regulation (EU) 2017/745
Title	Medical Devices Regulation (EU) 2017/745
Type	Regulation
Issued	2017
Jurisdiction	European Union
Status	In force

Medical Devices Regulation (EU) 2017/745 is a European Union legislative act that revised the legal framework for medical devices across the European Union and replaced the previous Medical Devices Directive 93/42/EEC and Active Implantable Medical Devices Directive 90/385/EEC. The regulation introduced stricter requirements for device clinical evaluation, post-market surveillance, and conformity assessment, aiming to strengthen patient safety, traceability, and market transparency. It has driven regulatory realignment among manufacturers, notified bodies, and national competent authorities such as those in Germany, France, Italy, and Spain.

Background and Legislative History

The regulation emerged from policy responses to high-profile device controversies and public inquiries including scrutiny in France and debates in the European Parliament following cases linked to breast implant failures and hip replacement recalls. Legislative development involved the European Commission, the Council of the European Union, and the European Parliament under the ordinary legislative procedure, with negotiations drawing on reports from bodies like the European Chemicals Agency and input from stakeholders such as the European Federation of Pharmaceutical Industries and Associations and the European Patients' Forum. Its adoption in 2017 followed earlier regulatory reform attempts including the Global Harmonization Task Force deliberations and was influenced by international standards from organizations like the International Organization for Standardization and the International Electrotechnical Commission.

Scope and Definitions

The regulation broadened scope to include devices previously outside direct coverage, aligning definitions with terminology used by the World Health Organization and the International Medical Device Regulators Forum. Novel definitions introduced or clarified terms related to medical device software, in vitro diagnostic device interfaces, and accessories, with explicit treatment of devices incorporating nanomaterials and devices manufactured using 3D printing technology. It distinguished between implantable devices, active devices, and general devices, affecting stakeholders including national authorities such as the Medicines and Healthcare products Regulatory Agency and trade associations like MedTech Europe.

Classification and Conformity Assessment

The regulation revised classification rules, notably raising classification levels for certain devices previously classed lower under the MEDDEV guidance, which impacted product portfolios for companies ranging from multinational corporations like Siemens Healthineers and GE Healthcare to small and medium enterprises represented by MedTech Innovator. Conformity assessment routes now require involvement of designated notified bodies for higher-risk classes, and manufacturers must implement quality management systems aligned with harmonized standards such as ISO 13485. The change affected devices including active implantable devices used in specialties associated with institutions like Mayo Clinic, Cleveland Clinic, and universities including University College London and Karolinska Institutet.

Clinical Evaluation and Post‑Market Surveillance

Clinical evaluation requirements were strengthened, referencing methodologies from the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance and harmonized clinical study expectations similar to those overseen by regulatory authorities like the European Medicines Agency and the U.S. Food and Drug Administration. Manufacturers must maintain clinical evaluation reports, compile periodic safety update reports, and implement proactive post-market surveillance systems interoperable with databases such as the European Databank on Medical Devices and national vigilance systems in countries like Belgium and Netherlands. The regulation emphasized evidence from real-world data sources including registries supported by organizations like International Consortium of Orthopaedic Registries.

Notified Bodies and Market Access

Designation and oversight of notified bodies became more stringent, with conformity assessment capacity assessed by national accreditation bodies such as UKAS and COFRAC and coordination through the European Commission's mechanisms. The reduced number and enhanced scrutiny of notified bodies influenced market access pathways for manufacturers including legacy firms like Medtronic and emerging startups spun out of research at institutions such as ETH Zurich. The Unique Device Identification requirements and EUDAMED database interactions required suppliers, distributors, and authorised representatives to align commercial procedures across markets including Poland and Sweden.

Transitional Provisions and Implementation Challenges

Transitional timelines accommodated device lifecycles and certificate validity while phasing in new obligations, with final dates prompting industry migration efforts akin to prior regulatory shifts experienced by sectors regulated under laws like the General Data Protection Regulation. Challenges included notified body capacity shortages, harmonization of clinical evidence expectations, and supply chain impacts affecting procurement agencies in hospitals affiliated with networks such as NHS England and purchasing consortia like Groupement d'Intérêt Public. Legal and operational disputes occasionally reached national courts and were subject to review by advisory bodies such as the European Court of Auditors.

Impact on Industry and Healthcare Systems

The regulation increased compliance costs and shifted risk management responsibilities, prompting strategic responses from manufacturers including mergers and acquisitions involving corporations like Becton Dickinson and Boston Scientific, and driving investment in regulatory affairs functions often recruited from academic centers such as Sorbonne University. Healthcare providers and procurement bodies faced changes in device availability, tendering, and lifecycle management, influencing clinical practice in specialties at institutions like Johns Hopkins Hospital and Massachusetts General Hospital. Overall, the regulation aimed to harmonize safety and performance standards across the European Single Market while generating secondary effects on innovation pathways, market consolidation, and international trade relations with partners including United States, China, and Japan.

Category:European Union regulations on medical devices